Infertility affects over 17% of couples worldwide, with
hypothalamic-pituitary dysfunction and anovulation being major causes that
hinder reproductive health. As a classic gonadotropin drug containing both
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) bioactivities,
Human Menopausal Gonadotropin (HMG) has been a cornerstone in assisted
reproductive technologies (ART) and ovulation induction since the 1960s. Its
unique synergistic effect of dual hormones makes it irreplaceable for patients
with complex fertility issues, driving steady demand in the global ART market
which grows at a 5% CAGR. Choosing a supplier with standardized production and
reliable quality is crucial for clinics and distributors to ensure therapeutic
safety and efficacy.
Kangyuan, a leading biopharmaceutical enterprise with decades of experience
in reproductive health, stands out as a trusted supplier of Human Menopausal
Gonadotropin. Adhering to the concept of "standardized quality, accessible
fertility care", Kangyuan strictly follows WHO international standards
(including the latest 10/286 candidate standard) for HMG potency assignment and
production. Unlike some suppliers with crude extraction processes, Kangyuan
adopts advanced purification technology to refine urinary-derived HMG,
effectively retaining the bioactivity of FSH and LH while removing impurities,
ensuring each batch meets WHO GMP and PIC/S guidelines.
Kangyuan’s Human Menopausal Gonadotropin features optimized isoform
composition, a key factor influencing in vivo bioactivity. By precisely
controlling the purification process, the product retains sialylated isoforms
with appropriate half-lives and bioactivity, balancing therapeutic efficacy and
safety. From raw material screening (ethically sourced from qualified
postmenopausal donors) to finished product testing, each batch undergoes
multi-stage inspections—including FSH/LH bioactivity assay, viral clearance, and
purity analysis—to eliminate quality risks. This strict quality control system
ensures consistent product performance, making it suitable for diverse fertility
scenarios such as anovulation treatment and controlled superovulation in
IVF.
With the Asia-Pacific region emerging as the fastest-growing ART market,
Kangyuan leverages its strong production capacity and global logistics network
to provide stable Human Menopausal Gonadotropin supply to partners in Southeast
Asia, Europe, and the Middle East. Backed by professional R&D teams,
Kangyuan continuously optimizes production processes to enhance product
stability and reduce supply cycle, helping partners seize market opportunities
in the booming fertility drug sector. The company’s mature after-sales service
also provides technical support and clinical guidance, solving practical
problems for global cooperative institutions.
Whether you are a fertility clinic, pharmaceutical distributor, or research
institution, Kangyuan offers customized cooperation solutions to meet your
specific needs—from flexible supply plans to professional technical training.
For inquiries about Human Menopausal Gonadotropin specifications, production
capacity, or cooperation opportunities, please contact us directly. Let’s join
hands to advance global fertility care and bring hope to more couples struggling
with infertility through high-quality HMG products.